BLOG

precision_oncology

High MAPK Activity May Predict MEK Inhibitor Benefit for RAS-Mutated Cancer Patients, Study Finds

By measuring the functional MAPK activity of different RAS mutations, researchers have developed a method they believe could help identify patients with RAS-mutated cancers likely to benefit from MEK inhibitors like trametinib (Novartis’ Mekinist).

Back to the Blog .st0{stroke:#000;stroke-width:3}.st0,.st1{fill:none}